Log in
Log in
E-mail
Password

Show password
Remember
Forgot password ?
Become a member for free
Sign up
Become a member for free
Sign up
New member
Sign up for FREE
New customer
Discover our services
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Biovica International AB (publ)
  6. News
  7. Summary
    BIOVIC B   SE0008613731

BIOVICA INTERNATIONAL AB (PUBL)

(BIOVIC B)
  Report
Delayed Quote. Delayed Nasdaq Stockholm - 05/27 11:29:33 am
37.75 SEK   +8.63%
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum®TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum®TKa to the FDA
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Biovica International AB Provides Earnings Guidance for the Full Year 2021

12/01/2021 | 01:30am EDT
share with twitter
share with LinkedIn
share with facebook

Biovica International AB (publ) provided earnings guidance for the full year 2021. For the period, the company sales are expected to be lower due to the delay in processing of the 510(k) application.


© S&P Capital IQ 2021
All news about BIOVICA INTERNATIONAL AB (PUBL)
05/17TRANSCRIPT : Biovica International AB - Analyst/Investor Day
CI
05/09Biovica's DiviTum®TKa at ASCO
AQ
04/28Biovica completes 510(k) submission for DiviTum®TKa to the FDA
AQ
04/28Biovica completes 510(k) submission for DiviTum®TKa to the FDA
CI
04/28Biovica Capital Markets Day invitation May 17, 2022
AQ
03/22Positive DiviTum®TKa results published in npj Breast Cancer
AQ
03/15TRANSCRIPT : Biovica International AB, Q3 2022 Earnings Call, Mar 15, 2022
CI
03/15Biovica International AB Provides Earnings Guidance for the Full Year 2022
CI
03/15Biovica International AB Reports Earnings Results for the Third Quarter and Nine Months..
CI
03/14Biovica establishes US CLIA lab to further strengthen DiviTum®TKa launch
AQ
More news
Financials
Sales 2022 1,00 M 0,10 M 0,10 M
Net income 2022 -37,1 M -3,77 M -3,77 M
Net cash 2022 120 M 12,2 M 12,2 M
P/E ratio 2022 -19,6x
Yield 2022 -
Capitalization 1 075 M 109 M 109 M
EV / Sales 2022 955x
EV / Sales 2023 5,68x
Nbr of Employees 26
Free-Float 42,9%
Chart BIOVICA INTERNATIONAL AB (PUBL)
Duration : Period :
Biovica International AB (publ) Technical Analysis Chart | BIOVIC B | SE0008613731 | MarketScreener
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 37,75
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Anders Rylander Chief Executive Officer & Director
Cecilia Driving Chief Financial Officer, Executive VP & IR Contact
Lars Erik Holmqvist Chairman
Otti Bengtsson Gref Vice President-Research & Development
Tomas Andersson Vice President-Operations
Sector and Competitors
1st jan.Capi. (M$)
BIOVICA INTERNATIONAL AB (PUBL)-8.82%109
EXACT SCIENCES CORPORATION-30.84%9 471
GUARDANT HEALTH, INC.-57.01%4 383
BGI GENOMICS CO., LTD.-25.02%4 028
SEEGENE, INC.-28.77%1 792
BEIJING STRONG BIOTECHNOLOGIES, INC.-18.52%1 420